Usefulness of the 2012 European CVD risk assessment model to identify patients at high risk of cardiovascular events during nilotinib therapy in chronic myeloid leukemia

[1]  H. Dombret,et al.  Early onset hypercholesterolemia induced by the 2nd-generation tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronic myeloid leukemia , 2014, Haematologica.

[2]  D. White,et al.  Which TKI? An embarrassment of riches for chronic myeloid leukemia patients. , 2013, Hematology. American Society of Hematology. Education Program.

[3]  G. Superti-Furga,et al.  Nilotinib Exerts Direct Pro-Atherogenic and Anti-Angiogenic Effects On Vascular Endothelial Cells: A Potential Explanation For Drug-Induced Vasculopathy In CML , 2013 .

[4]  I. Flinn,et al.  ENESTnd Update: Nilotinib (NIL) Vs Imatinib (IM) In Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) and The Impact Of Early Molecular Response (EMR) and Sokal Risk At Diagnosis On Long-Term Outcomes , 2013 .

[5]  T. Chevassut,et al.  Genomic landscapes and clonality of de novo AML. , 2013, The New England journal of medicine.

[6]  Francisco Cervantes,et al.  European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. , 2013, Blood.

[7]  Alan D. Lopez,et al.  Measuring the global burden of disease. , 2013, The New England journal of medicine.

[8]  B. Dörken,et al.  Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib , 2013, Leukemia.

[9]  M. Haluzík,et al.  Mechanism of impaired glucose metabolism during nilotinib therapy in patients with chronic myelogenous leukemia , 2013, Haematologica.

[10]  O. Abdel-Wahab,et al.  The role of mutations in epigenetic regulators in myeloid malignancies , 2012, Nature Reviews Cancer.

[11]  Shah Ebrahim,et al.  European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) , 2012, International Journal of Behavioral Medicine.

[12]  H. Hock.  A complex Polycomb issue: the two faces of EZH2 in cancer. , 2012, Genes & development.

[13]  K. Döhner,et al.  Prognostic DNA methylation patterns in cytogenetically normal acute myeloid leukemia are predefined by stem cell chromatin marks. , 2011, Blood.

[14]  R. Latagliata,et al.  Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib , 2011, Haematologica.

[15]  B. Dörken,et al.  Severe peripheral arterial disease during nilotinib therapy. , 2011, Journal of the National Cancer Institute.

[16]  P. Valent,et al.  Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML , 2011, American journal of hematology.

[17]  R. Andrews,et al.  Mutant nucleophosmin and cooperating pathways drive leukemia initiation and progression in mice , 2011, Nature Genetics.

[18]  J. Radich,et al.  Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. , 2011, Blood.

[19]  Ricardo Pasquini,et al.  Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. , 2010, The New England journal of medicine.

[20]  Bob Löwenberg,et al.  Review Articles (434 articles) , 2008 .

[21]  E. Wagner,et al.  Metabolism and regulation of canonical histone mRNAs: life without a poly(A) tail , 2008, Nature Reviews Genetics.

[22]  Shah Ebrahim,et al.  Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts) , 2007 .

[23]  Bing Li,et al.  The Role of Chromatin during Transcription , 2007, Cell.

[24]  Kristian Helin,et al.  Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. , 2006, Genes & development.

[25]  Donna Neuberg,et al.  Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. , 2005, Cancer cell.

[26]  Shah Ebrahim,et al.  JOINT ESC GUIDELINES 2016 European Guidelines on cardiovascular disease prevention in clinical practice – Web Addenda , 2016 .